Treatment focuses on symptom management and is carried out by a multidisciplinary team. Currently, miglustat, (Zavesca™; Actelion Pharmaceuticals Ltd), inhibitor of the synthesis of GSLs is the first ...

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus ...

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan Provided by GlobeNewswire Jun 25, 2025, 4:00:00 AM ...

Date 2025-06-25 07:16:59 (MENAFN - GlobeNewsWire - Nasdaq) Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) ...

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus ...

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus ...

Pombiliti + Opfolda is a two-component therapy. Pombiliti (cipaglucosidase alfa-atga) is a bis-M6P-enriched rhGAA designed for high-affinity uptake and efficient processing. Opfolda (miglustat) is ...

TOKYO/PRINCETON - Japan’s Ministry of Health, Labour and Welfare has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe ...

Pombiliti ® + Opfolda ®, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining ...